14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.12 $1.72 Friday, 3rd May 2024 SLS stock ended at $1.33. This is 1.48% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 6.20% from a day low at $1.29 to a day high of $1.37.
90 days $0.562 $1.72
52 weeks $0.499 $1.91

Historical SELLAS Life Sciences Group Inc. prices

Date Open High Low Close Volume
May 03, 2024 $1.36 $1.37 $1.29 $1.33 772 389
May 02, 2024 $1.25 $1.35 $1.21 $1.35 1 207 820
May 01, 2024 $1.30 $1.44 $1.12 $1.28 9 447 375
Apr 30, 2024 $1.16 $1.28 $1.13 $1.24 1 093 298
Apr 29, 2024 $1.33 $1.34 $1.20 $1.21 3 302 729
Apr 26, 2024 $1.53 $1.55 $1.42 $1.46 1 279 322
Apr 25, 2024 $1.52 $1.58 $1.50 $1.52 635 129
Apr 24, 2024 $1.61 $1.63 $1.46 $1.54 1 309 142
Apr 23, 2024 $1.54 $1.72 $1.46 $1.63 2 015 350
Apr 22, 2024 $1.55 $1.62 $1.50 $1.54 1 461 124
Apr 19, 2024 $1.54 $1.57 $1.47 $1.54 1 787 304
Apr 18, 2024 $1.46 $1.53 $1.40 $1.52 1 555 247
Apr 17, 2024 $1.34 $1.45 $1.32 $1.41 560 689
Apr 16, 2024 $1.32 $1.41 $1.28 $1.36 1 206 025
Apr 15, 2024 $1.30 $1.37 $1.27 $1.33 804 912
Apr 12, 2024 $1.40 $1.42 $1.30 $1.34 1 103 417
Apr 11, 2024 $1.39 $1.41 $1.31 $1.40 500 303
Apr 10, 2024 $1.38 $1.48 $1.33 $1.39 908 697
Apr 09, 2024 $1.47 $1.49 $1.25 $1.40 2 202 924
Apr 08, 2024 $1.38 $1.49 $1.36 $1.45 2 198 145
Apr 05, 2024 $1.30 $1.35 $1.26 $1.34 940 373
Apr 04, 2024 $1.32 $1.36 $1.26 $1.29 2 020 743
Apr 03, 2024 $1.25 $1.33 $1.18 $1.31 2 637 655
Apr 02, 2024 $1.10 $1.24 $1.07 $1.18 2 345 759
Apr 01, 2024 $1.03 $1.08 $0.98 $1.07 1 579 104
Click to get the best stock tips daily for free!

About SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group. SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cance... SLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT